Yes, Ripretinib, marketed under the brand name Qinlock, is FDA approved. The U.S. Food and Drug Administration (FDA) approved Ripretinib on May 15, 2020, for the treatment of advanced gastrointestinal stromal tumor (GIST) in adult patients who have received prior treatment with three or more kinase inhibitors, including imatinib.
Ripretinib is an oral multikinase inhibitor used to treat tumors of the stomach and intestines, specifically gastrointestinal stromal tumors (GIST). It is indicated for use in adults who have already been treated with at least three other cancer medicines.
Ripretinib targets multiple kinases involved in cancer cell growth, including KIT and PDGFRA kinases. These kinases are often mutated in GIST, driving tumor growth. By inhibiting these kinases, Ripretinib can help slow or stop the progression of the disease.
Ripretinib is available in oral tablet form (50 mg). The recommended dose for adults is 150 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. Tablets should be swallowed whole and not crushed, chewed, or broken.
Common side effects of Ripretinib include:
Serious side effects may include:
Ripretinib (Qinlock) is a targeted therapy approved by the FDA for the treatment of advanced GIST in patients who have previously been treated with multiple kinase inhibitors. Approved on May 15, 2020, it offers a new option for patients with this challenging and aggressive form of cancer. As with any medication, it is essential to follow the prescribing doctor's instructions and report any side effects promptly.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!